Iron chelation therapy in myelodysplastic syndromes

被引:3
作者
Fausel, Christopher A. [1 ]
机构
[1] Indiana Univ, Simon Canc Ctr, Sch Med, Div Hematol Oncol,Oncol Pharm Serv, Indianapolis, IN 46202 USA
关键词
Anemia; Blood; Colony stimulating factors; Deferasirox; Deferoxamine; Diagnosis; Economics; Epidemiology; Heavy metal antagonists; Iron overload; Myelodysplastic syndromes; Phlebotomy; Toxicity; MDS PATIENTS; OVERLOAD; DEFERASIROX; MANAGEMENT; IMPACT;
D O I
10.2146/ajhp090654
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. To understand how to appropriately recognize and manage iron overload with iron chelation therapy (ICT) in patients with myelodysplastic syndromes (MDS), evaluation of the role of different agents available for management of iron overload, including efficacy, safety, and economic considerations for transfusion-dependent patients with MDS, is provided. Summary. Patients with MDS have a high incidence of anemia, which often requires treatment. Supportive care measures such as red blood cell transfusions and erythroid colony stimulating factors are mainstays of therapy. Use of long-term transfusion therapy has limitations in patients with MDS due to the risk of developing iron overload. Strategies to manage iron overload include phlebotomy and ICT with agents such as deferoxamine and deferasirox. Data evaluating pharmacologic therapy for treatment of iron overload in patients with MDS suggest timely intervention can mitigate the morbidity associated with this clinical syndrome. Conclusion. Development of practical management strategies to implement and optimize ICT using deferoxamine and deferasirox will be important to provide optimal care for transfusion-dependent patients with MDS.
引用
收藏
页码:S10 / S15
页数:6
相关论文
共 26 条
[1]  
[Anonymous], EARL COMM ONG SAF RE
[2]  
[Anonymous], NCCN CLIN PRACT GUID
[3]  
*APOT EUR BV, 2004, FERR DEF 500 MG FILM
[4]   Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients - US healthcare system perspective [J].
Delea, Thomas E. ;
Sofrygin, Oleg ;
Thomas, Simu K. ;
Baladi, Jean-Francois ;
Phatak, Pradyumna D. ;
Coates, Thomas D. .
PHARMACOECONOMICS, 2007, 25 (04) :329-342
[5]   The deleterious effects of iron overload in patients with myelodysplastic syndromes [J].
Dreyfus, Francois .
BLOOD REVIEWS, 2008, 22 :S29-S34
[6]   Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload [J].
Gattermann, Norbert .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (01) :24-29
[7]  
Gattermann N, 2008, BLOOD, V112, P235
[8]  
Greenberg Peter L, 2006, J Natl Compr Canc Netw, V4, P91
[9]  
Greenberg Peter L, 2008, J Natl Compr Canc Netw, V6, P942
[10]   Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes [J].
Jabbour, Elias ;
Kantarjian, Hagop M. ;
Koller, Charles ;
Taher, Ali .
CANCER, 2008, 112 (05) :1089-1095